EUVIMEDEUVIMED entdecken
Crossref

Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma

Victor Robic, Maxime Collin, Jules Dupont, Ghina Jardali, Aurélie Choucair, Lama Dawi, Littisha Lawrance, Vincent Goldschmidt, Christophe Massard, Cristina Smolenschi, Michel Ducreux, Thomas Pudlarz und 9 weitere

European Journal of Cancer · 2026-06 · 241 · 116768

DOI: 10.1016/j.ejca.2026.116768 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Victor Robic und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Oncologic Imaging, Gustave Roussy Institute, Villejuif F-94805, France; Biomaps, UMR1281, INSERM, Centre National de la Rech…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Tumor Burden, Biomarkers, Tumor. Die Arbeit nennt 31 Literaturangaben. Gefördert von: French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Tumor volumetry and liquid biopsy are emerging tools reflecting tumor burden and enhancing prognostic assessment in advanced pancreatic ductal adenocarcinoma (PDAC). METHODS: This retrospective monocentric study of 102 advanced PDAC patients assessed the prognostic value of total tumor volume (TTV), measured on CT-scans, and circulating tumor fraction (TF) at diagnosis. Liquid biopsy provided the TF and variant allele frequency (VAF) of mutations. All cutoff values were determined by maximizing Youden's index. Overall survival (OS) was analyzed using Kaplan-Meier and Cox models. Patients were stratified into high and low TTV groups according to the TTV threshold; the same approach was applied to TF. A composite prognostic score integrating TTV and TF categories stratified patients into high- and low-risk OS groups. Pearson and Spearman coefficients assessed correlations between TTV, TF, and VAFs. RESULTS: Among 102 patients (7927 lesions manually annotated), patients in high TTV group had a significantly shorter OS than those in low TTV group (cutoff ≥ 211 cm3, HR=1.78, p = 0.02). Similarly, patients in high TF group had a significantly shorter OS than those in low TF group (cutoff ≥ 5%, HR=1.84, p = 0.01). The combined TTV-TF score showed the strongest prognostic value (HR=2.09, p < 0.005). Furthermore, TTV correlated with TF (Spearman r = 0.70), TP53 VAF (Pearson R2=0.49) and KRAS VAF (Spearman r = 0.54). CONCLUSIONS: Early integration of tumor volumetry and ctDNA profiling refines advanced PDAC prognosis. The combined TTV-TF score offers greater prognostic value than either parameter alone, to be validated in a larger prospective cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsTumor BurdenBiomarkers, TumorCirculating Tumor DNAHumansFemaleRetrospective StudiesPrognosisAgedMaleLiquid BiopsyMiddle AgedMutationTomography, X-Ray ComputedAged, 80 and over

Stichwörter der Autor:innen

Advanced pancreatic adenocarcinomaCT-scanCtDNALiquid biopsyPrognosisTotal tumor volume

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Diagnostic Oncologic Imaging, Gustave Roussy Institute, Villejuif F-94805, France; Biomaps, UMR1281, INSERM, Centre National de la Recherche Scientifique (CNRS), Commissariat à l'Energie Atomique (CEA), Un…
  • Department of Medical Oncology (DMO), Gustave Roussy, Villejuif, France.
  • IHU PRISM, National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France; Faculty of Medicine, Paris Saclay University, Paris, France; Department of Therapeutics Innovation (DITEP), Gustave Roussy, V…
  • Department of Medical Oncology (DMO), Gustave Roussy, Villejuif, France; Department of Therapeutics Innovation (DITEP), Gustave Roussy, Villejuif, France.
  • Department of Medical Oncology (DMO), Gustave Roussy, Villejuif, France; Faculty of Medicine, Paris Saclay University, Paris, France.
  • IHU PRISM, National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France; Department of Therapeutics Innovation (DITEP), Gustave Roussy, Villejuif, France.

Förderung

  • French National Research Agency

Zitieren

APA

Robic, V., Collin, M., Dupont, J., Jardali, G., Choucair, A., Dawi, L., Lawrance, L., Goldschmidt, V., Massard, C., Smolenschi, C., Ducreux, M., Pudlarz, T., Facchinetti, F., Camilleri, G. M., Valery, M., Boige, V., Tarabay, A., Italiano, A., Hollebecque, A., …, & Lassau, N. (2026). Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. European Journal of Cancer, 241, 116768. https://doi.org/10.1016/j.ejca.2026.116768

Vancouver

Robic V, Collin M, Dupont J, Jardali G, Choucair A, Dawi L, et al. Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. European Journal of Cancer. 2026;241:116768. doi:10.1016/j.ejca.2026.116768

BibTeX
@article{Robic2026,
  author = {Robic, Victor and Collin, Maxime and Dupont, Jules and Jardali, Ghina and Choucair, Aurélie and Dawi, Lama and Lawrance, Littisha and Goldschmidt, Vincent and Massard, Christophe and Smolenschi, Cristina and Ducreux, Michel and Pudlarz, Thomas and Facchinetti, Francesco and Camilleri, Géraldine M and Valery, Marine and Boige, Valérie and Tarabay, Anthony and Italiano, Antoine and Hollebecque, Antoine and Boilève, Alice and Lassau, Nathalie},
  title = {Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {241},
  pages = {116768},
  doi = {10.1016/j.ejca.2026.116768}
}
Kostenlos starten →